Plantext

PlantEXT Ltd. is pioneering proprietary and effective medical cannabis (medical marijuana) formulations that are backed by science and clinical studies for the treatment of inflammation and inflammation-based illnesses. Led by the world’s top R&D and product commercialization experts, PlantEXT’s mission is to assure the highest quality, clinically evidenced, safe and effective medical cannabis solutions that solve unmet needs for the consumer. The PlantEXT innovative approach to development is based on the knowledge and years of experience our team holds in the pharmaceutical industry, from discovery and feasibility to cGMP. With roots in both Canada and Israel, the hotbeds of cannabis innovation and commercialization; PlantEXT is positioned at the forefront of science-based medical cannabis product development. PlantEXT is developing and commercializing high profile, high margin and fast to market cannabis based medical products that have been proven to be truly effective solutions through proprietary research and validation techniques. PlantEXT has entered into a license agreement with The Government of the State of Israel and has funded research at ARO thus acquiring the exclusive global rights to commercialize ARO’s intellectual property (“IP”) and products based on formulations of active cannabis compounds and possibly other pharmaceutical drugs as a basis for development of products for the treatment of lung inflammation such as the inflammation provoked by COVID-19 and Inflammatory Bowel Disease. PlantEXT is currently working on treatments for dermatological diseases such as Psoriasis and Atopic Dermatitis and solutions for Pain and Migraine. In addition, PlantEXT is honored to be a part of an important and prestigious joint venture that is working on R&D related to the endocannabinoid system and is showing remarkable and exciting potential to treat addiction as a disease.